Quantitative MRI of Glioblastoma Response

胶质母细胞瘤反应的定量 MRI

• 批准号: 8659191
• 负责人: Jayashree Kalpathy-Cramer
• 金额: $ 57.52万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-06 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8659191
• 关键词: Adverse effects; Algorithms; American College of Radiology Imaging Network; Biological Markers; Blood; Blood Vessels; Clinical; Clinical Trials; Core-Binding Factor; Data; Decision Making; Diffusion; Extravasation; Gadolinium; Glioblastoma; Human; Image; Instruction; Magnetic Resonance Imaging; Malignant neoplasm of brain; Measurement; Methods; Multicenter Studies; National Cancer Institute; Oncologist; Patients; Performance; Permeability; Predisposition; Principal Investigator; Process; Progression-Free Survivals; Property; Publishing; Research; Retrospective Studies; Scientist; Techniques; The Sun; Work; base; bevacizumab; cancer therapy; clinical decision-making; ferumoxytol; gadolinium oxide; imaging modality; improved; indexing; outcome forecast; prognostic; prospective; response; simulation; tool; tumor

DESCRIPTION (provided by applicant): Assessment of anti-angiogenic therapies for the most severe form of brain cancer, glioblastoma, is extremely timely given the recent approval of bevacizumab yet the moderate response rate and the challenging side effects of these therapies. Clinical decision-making tools are badly needed; fortunately, our recently published data suggest that measurement of microvascular properties of the tumor using MRI and gadolinium-based approaches could be very useful, as with proper quantitation these methods appear to be capable of serving as an effective prognostic imaging biomarker, and may be beneficially combined with blood biomarkers. We propose to join the NCI's Quantitative Imaging Network (QIN) and develop improved analysis methods for dynamic contrast enhanced MRI and dynamic susceptibility MRI that will improve quantification and decrease variability. We propose to develop techniques that will be applicable in the multicenter setting through a bottom-up approach of simulations, phantom studies, retrospective analysis, and prospective analysis in patients undergoing treatment with anti-angiogenic therapies. We anticipate that our proposed approach, in particular through working in close harmony with the QIN, will improve the reliability of advanced microvascular MRI methods as potential imaging biomarkers, and pave the way for a clinically useful decision-making tool. RELEVANCE (See instructions): Advanced MRI methods may improve our ability to provide an accurate prognosis and potentially guide treatment choices for glioblastoma patients. Our proposed research will help establish a common, standardized approach to acquisition and analysis of two forms of vascular MRI that have shown excellent promise. We will do this by careful reduction of variability and by close participation in the National Cancer Institute's Quantitative Imaging Network. These efforts will enable these advanced techniques to become more widely available and more appropriately establish their benefit to patients.

描述（由申请方提供）：鉴于贝伐珠单抗最近获得批准，但这些治疗的缓解率中等且副作用具有挑战性，因此对最严重形式的脑癌（胶质母细胞瘤）的抗血管生成治疗进行评估非常及时。临床决策工具是迫切需要的;幸运的是，我们最近发表的数据表明，使用MRI和基于钆的方法测量肿瘤的微血管特性可能非常有用，因为通过适当的定量，这些方法似乎能够作为一种有效的预后成像生物标志物，并可能与血液生物标志物有益地结合。我们建议加入NCI的定量成像网络（QIN），并为动态对比增强MRI和动态磁化率MRI开发改进的分析方法，以提高定量和降低变异性。我们建议通过模拟、体模研究、回顾性分析和前瞻性分析的自下而上方法，在接受抗血管生成治疗的患者中开发适用于多中心环境的技术。我们预计，我们提出的方法，特别是通过与QIN密切合作，将提高先进微血管MRI方法作为潜在成像生物标志物的可靠性，并为临床有用的决策工具铺平道路。相关性（参见说明）：先进的MRI方法可以提高我们提供准确预后的能力，并可能指导胶质母细胞瘤患者的治疗选择。我们提出的研究将有助于建立一个共同的，标准化的方法来获取和分析两种形式的血管MRI，已显示出良好的前景。我们将通过仔细减少变异性和密切参与国家癌症研究所的定量成像网络来做到这一点。这些努力将使这些先进的技术变得更广泛，并更适当地确定其对患者的益处。